Our Tetanus Vaccine Development
L-Vac has been tested for development of a freeze-dried tetanus vaccine together with a recombinant protein antigen (TLC). The immune response in mice against tetanus toxoid was increased by twenty-eight-fold compared to when TLC was administered alone (Figure 1b).
Engimata has a COVID-19 vaccine and a tetanus vaccine in the pipeline (preclinical stage). Unlike current vaccines they can both be distributed without a need for a cold or ultracold supply chain, improving immunization logistics. Engimata’s vaccine is cost-effective, easy to scale up, and simple to manufacture and distribute outside the cold supply chain. This increases vaccine accessibility and stability, ultimately saving cost, resources, and lives.